Chemoimmunotherapy: a Promising Novel Combination Therapy for Advanced Prostate Cancers

Chemoimmunotherapy: a Promising Novel Combination Therapy for Advanced Prostate Cancers
A new study published in the journal Nature revealed a promising new combination therapy for advanced prostate cancers that are typically non-responsive to chemotherapy. The study is entitled “Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy” and was conducted by a team led by researchers at the University of California, San Diego. Prostate cancer is the second most common cancer in men, with almost one million new cases diagnosed every year worldwide. It is estimated that one in every seven men will be diagnosed with this cancer during their lifetimes. It is a curable cancer that can range from slow-growing tumors (more common) to rapidly progressing aggressive tumors. Advanced or metastatic prostate cancers usually are non-responsive to chemotherapy. Prostate cancers are also non-responsive to an encouraging new type of drugs based on immunotherapy called checkpoint inhibitors, which are drugs able to trigger a stronger immune response to better fight cancer. It has been suggested that this resistance to treatment is in part due to the accumulation of cells that suppress the body’s immune response, namely immunosuppressive immune B cells. These cells can control the immune system, negatively interfering with cancer therapies and allowing the growth of malignant tumors despite treatment. Immunosuppressive B cells are often found in larger prostate cancers in mice and in advanced and metastatic prostate cancers in humans. In the study, researchers us
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *